(Total Views: 201)
Posted On: 10/13/2022 4:47:19 AM
Post# of 25498
$RGC is defending itself against short sellers.
RGC has received a lot of short and unfavorable market commentary from sceptics. During this time, the company's CEO (Mr Au) has been purchasing back shares for $5 million.
Regencell Bioscience Holdings (RGC: Nasdaq) is a bioscience healthcare firm in the early stages that focuses on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
The firm has recently been on an upward trajectory, demonstrating its endurance in uncertain times, thanks to its main industry: healthcare.
Healthcare stocks, for example, have demonstrated through time that they are resistant to market volatility and are highly regarded by institutional investors and fund managers.
Despite being severely shorted in the early months of Q2 22', the firm stock has been on an upward trend despite the massive sell-off in several market sectors, particularly the growth stock and cryptocurrency markets.
RGC has received a lot of short and unfavorable market commentary from sceptics. During this time, the company's CEO (Mr Au) has been purchasing back shares for $5 million.
Regencell Bioscience Holdings (RGC: Nasdaq) is a bioscience healthcare firm in the early stages that focuses on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
The firm has recently been on an upward trajectory, demonstrating its endurance in uncertain times, thanks to its main industry: healthcare.
Healthcare stocks, for example, have demonstrated through time that they are resistant to market volatility and are highly regarded by institutional investors and fund managers.
Despite being severely shorted in the early months of Q2 22', the firm stock has been on an upward trend despite the massive sell-off in several market sectors, particularly the growth stock and cryptocurrency markets.
(0)
(0)
